Piper Sandler analyst Matt O’Brien raised the firm’s price target on Globus Medical (GMED) to $100 from $80 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 results which again solidly beat on the top and bottom lines. The company raised FY guidance, albeit by less than the beat, though management noted clear conservatism with this move, Piper says. The firm believes there is a lot to like in the name.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $87 from $78 at BTIG
- Globus Medical price target raised to $80 from $55 at BofA
- Globus Medical price target raised to $88 from $78 at Wells Fargo
- Globus Medical Reports Robust Q3 2024 Financial Growth
- Closing Bell Movers: Exact Sciences falls 30% after results, guidance cut